纳武利尤单抗单药治疗复发或转移性宫颈、阴道或外阴癌:CheckMate 358 I/II期试验结果
CheckMate 358 I/II期试验评估纳武利尤单抗240 mg每2周方案治疗复发/转移性宫颈、阴道或外阴癌患者。24例患者中,宫颈癌客观缓解率为26.3%(95%CI 9.1-51.2),阴道/外阴癌为20.0%(95%CI 0.5-71.6)。宫颈癌中位总生存期为21.9个月(95%CI 15.1-未达到),未发现新的安全性信号。
要点
- 宫颈癌客观缓解率26.3%,阴道/外阴癌20.0%。
- 宫颈癌中位总生存期21.9个月(95%CI 15.1-未达到)。
- 安全性可控,无治疗相关死亡,未发现新信号。
核心结论
- 纳武利尤单抗在复发/转移性宫颈、阴道或外阴癌中显示出有前景的疗效,值得进一步研究。
- 该人群中未发现新的安全性信号。
研究设计与样本
- I/II期CheckMate 358试验(NCT02488759)中评估纳武利尤单抗的队列。
- 患者接受纳武利尤单抗240 mg每2周一次。
- 入组24例患者:宫颈癌19例,阴道/外阴癌5例。
- 主要终点为客观缓解率;次要终点包括缓解持续时间、无进展生存期和总生存期;安全性和患者报告结局为探索性终点。
主要发现
- 宫颈癌客观缓解率为26.3%(95%CI 9.1-51.2);阴道/外阴癌为20.0%(95%CI 0.5-71.6)。
- 中位随访19.2个月时,宫颈癌队列5例缓解者的中位缓解持续时间未达到(范围23.3至29.5+个月,+表示删失观测);阴道/外阴癌队列唯一缓解者的缓解持续时间为5.0个月。
- 宫颈癌患者中位总生存期为21.9个月(95%CI 15.1个月-未达到)。
- 宫颈癌队列19例中12例(63.2%)报告任何级别治疗相关不良事件;阴道/外阴癌队列全部5例报告;无治疗相关死亡。
- 宫颈癌队列中,纳武利尤单抗治疗通常使与健康状况和健康相关生活质量相关的患者报告结局保持稳定。
临床怎么用
- 对于复发/转移性宫颈、阴道或外阴癌,纳武利尤单抗单药可作为探索性治疗选择,尤其宫颈癌缓解率较高且生存期可观。
- 治疗期间需监测治疗相关不良事件,但未发现新的安全性信号。
局限性
- 样本量小(宫颈癌19例,阴道/外阴癌5例)。
- 阴道/外阴癌队列客观缓解率置信区间宽(95%CI 0.5-71.6),仅1例缓解。
- 为I/II期单臂试验,无对照组。
- 人乳头瘤病毒阴性肿瘤患者被排除,结果可能不适用于该人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759). We report on patients with recurrent/metastatic cervical, vaginal, or vulvar cancers. PATIENTS AND METHODS: Patients received nivolumab 240 mg every 2 weeks. Although patients with unknown human papillomavirus status were enrolled, patients known to have human papillomavirus-negative tumors were ineligible. The primary end point was objective response rate. Duration of response (DOR), progression-free survival, and overall survival were secondary end points. Safety and patient-reported outcomes were exploratory end points. RESULTS: Twenty-four patients (cervical, n = 19; vaginal/vulvar, n = 5) were enrolled. Most patients had received prior systemic therapy for metastatic disease (cervical, 78.9%; vaginal/vulvar, 80.0%). Objective response rates were 26.3% (95% CI, 9.1 to 51.2) for cervical cancer and 20.0% (95% CI, 0.5 to 71.6) for vaginal/vulvar cancers. At a median follow-up of 19.2 months, median DOR was not reached (range, 23.3 to 29.5+ months; + indicates a censored observation) in the five responding patients in the cervical cohort; the DOR was 5.0 months in the single responding patient in the vaginal/vulvar cohort. Median overall survival was 21.9 months (95% CI, 15.1 months to not reached) among patients with cervical cancer. Any-grade treatment-related adverse events were reported in 12 of 19 patients (63.2%) in the cervical cohort and all five patients in the vaginal/vulvar cohort; there were no treatment-related deaths. In the cervical cohort, nivolumab treatment generally resulted in stabilization of patient-reported outcomes associated with health status and health-related quality of life. CONCLUSION: The efficacy of nivolumab in patients with recurrent/metastatic cervical and vaginal or vulvar cancers is promising and warrants additional investigation. No new safety signals were identified with nivolumab treatment in this population.
引用
- Naumann RW, Hollebecque A, Meyer T, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol. 2019. PMID: 31487218. doi:10.1200/JCO.19.00739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。